CRISPR Therapeutics AG (CRSP) Gains from Sales and Divestitures (2016 - 2026)

CRISPR Therapeutics AG has disclosed Gains from Sales and Divestitures across 11 years of filings, most recently posting $349508.0 for Q1 2026.

• Gains from Sales and Divestitures for Q1 2026 came in at $349508.0, down 11.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $349508.0 (down 11.95% YoY), and the FY2025 annual result was $736238.0, up 63.35% from the prior year.
• Gains from Sales and Divestitures came in at $349508.0 for Q1 2026 at CRISPR Therapeutics AG, down from $736238.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $736238.0 in Q4 2025 to a low of $123564.0 in Q1 2022.
• The 5-year median for Gains from Sales and Divestitures is $277808.0 (2023), against an average of $332802.8.
• Across the five-year window, Gains from Sales and Divestitures sank 47.76% in 2022 and surged 95.72% in 2023, its largest moves.
• CRISPR Therapeutics AG's Gains from Sales and Divestitures stood at $237932.0 in 2022, then gained by 16.76% to $277808.0 in 2023, then soared by 62.23% to $450701.0 in 2024, then soared by 63.35% to $736238.0 in 2025, then sank by 52.53% to $349508.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $349508.0 (Q1 2026), $736238.0 (Q4 2025), and $590587.0 (Q3 2025), per Business Quant data.